Neumirna awarded a Eureka Network EUROSTARS grant of 1.65M€ in collaboration with Motac Neuroscience Ltd, the Université de Bordeaux and the Center for RNA Medicine!

This grant will enable us to develop innovative RNA therapies which could revolutionize the treatment of Parkinson's Disease.

This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).

In 2021, Neumirna was selected and awarded by the US Epilepsy Foundation as being a promising start-up to advance new treatments for people with epilepsy in the EVF global accelerator course for start-up companies.